Acción AGN ALGERNON PHARMACEUTICALS INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Algernon Pharmaceuticals Inc.

Acciones

AGN

CA01559R4008

Mercado cerrado - Canadian Securities Exchange
Otros sitios de cotización
 20:50:41 10/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,125 CAD +13,64 % Gráfico intradía de Algernon Pharmaceuticals Inc. +13,64 % +92,31 %
30/04 Algernon Pharmaceuticals Inc. informa de los resultados del segundo trimestre y de los seis meses finalizados el 29 de febrero de 2024 CI
01/04 Algernon Pharmaceuticals seguirá adelante con su programa de investigación de la droga psicodélica Dmt para el ictus como principal activo CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company
Canadian Investment Regulatory Organization Trade Resumption - AGN
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Canadian Investment Regulatory Organization Trading Halt - AGN
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción AGN
  4. Noticias Algernon Pharmaceuticals Inc.
  5. Otros idiomas